Literature DB >> 20110411

COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems.

Hiroshi Katoh1, Kanako Hosono, Yoshiya Ito, Tatsunori Suzuki, Yasufumi Ogawa, Hidefumi Kubo, Hiroki Kamata, Toshiaki Mishima, Hideaki Tamaki, Hiroyuki Sakagami, Yukihiko Sugimoto, Shuh Narumiya, Masahiko Watanabe, Masataka Majima.   

Abstract

Bone marrow (BM)-derived hematopoietic cells, which are major components of tumor stroma, determine the tumor microenvironment and regulate tumor phenotypes. Cyclooxygenase (COX)-2 and endogenous prostaglandins are important determinants for tumor growth and tumor-associated angiogenesis; however, their contributions to stromal formation and angiogenesis remain unclear. In this study, we observed that Lewis lung carcinoma cells implanted in wild-type mice formed a tumor mass with extensive stromal formation that was markedly suppressed by COX-2 inhibition, which reduced the recruitment of BM cells. Notably, COX-2 inhibition attenuated CXCL12/CXCR4 expression as well as expression of several other chemokines. Indeed, in a Matrigel model, prostaglandin (PG) E2 enhanced stromal formation and CXCL12/CXCR4 expression. In addition, a COX-2 inhibitor suppressed stromal formation and reduced expression of CXCL12/CXCR4 and a fibroblast marker (S100A4) in a micropore chamber model. Moreover, stromal formation after tumor implantation was suppressed in EP3-/- mice and EP4-/- mice, in which stromal expression of CXCL12/CXCR4 and S100A4 was reduced. The EP3 or EP4 knockout suppressed S100A4+ fibroblasts, CXCL12+, and/or CXCR4+ stromal cells as well. Immunofluorescent analyses revealed that CXCL12+CXCR4+S100A4+ fibroblasts mainly comprised stromal cells and most of these were recruited from the BM. Additionally, either EP3- or EP4-specific agonists stimulated CXCL12 expression by fibroblasts in vitro. The present results address the novel activities of COX-2/PGE2-EP3/EP4 signaling that modulate tumor biology and show that CXCL12/CXCR4 axis may play a crucial role in tumor stromal formation and angiogenesis under the control of prostaglandins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110411      PMCID: PMC2832166          DOI: 10.2353/ajpath.2010.090607

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  70 in total

Review 1.  Role of myeloid cells in tumor angiogenesis and growth.

Authors:  Farbod Shojaei; Cuiling Zhong; Xiumin Wu; Lanlan Yu; Napoleone Ferrara
Journal:  Trends Cell Biol       Date:  2008-07-07       Impact factor: 20.808

Review 2.  Targeting prostaglandin E EP receptors to inhibit metastasis.

Authors:  Amy M Fulton; Xinrong Ma; Namita Kundu
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

3.  Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo.

Authors:  Reena Rao; Reyadh Redha; Ines Macias-Perez; Yan Su; Chuanming Hao; Roy Zent; Matthew D Breyer; Ambra Pozzi
Journal:  J Biol Chem       Date:  2007-03-31       Impact factor: 5.157

4.  Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.

Authors:  Eline Menu; Evy De Leenheer; Hendrik De Raeve; Les Coulton; Takeshi Imanishi; Kazuyuki Miyashita; Els Van Valckenborgh; Ivan Van Riet; Ben Van Camp; Richard Horuk; Peter Croucher; Karin Vanderkerken
Journal:  Clin Exp Metastasis       Date:  2006-11-03       Impact factor: 5.150

5.  Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.

Authors:  Mingfang Ao; Omar E Franco; Dean Park; Dayanidhi Raman; Karin Williams; Simon W Hayward
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

6.  CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

Authors:  Zhenhua Miao; Kathryn E Luker; Bretton C Summers; Rob Berahovich; Mahaveer S Bhojani; Alnawaz Rehemtulla; Celina G Kleer; Jeffrey J Essner; Aidas Nasevicius; Gary D Luker; Maureen C Howard; Thomas J Schall
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-26       Impact factor: 11.205

Review 7.  The role of CXC chemokines and their receptors in cancer.

Authors:  Jo Vandercappellen; Jo Van Damme; Sofie Struyf
Journal:  Cancer Lett       Date:  2008-06-24       Impact factor: 8.679

8.  Bv8 regulates myeloid-cell-dependent tumour angiogenesis.

Authors:  Farbod Shojaei; Xiumin Wu; Cuiling Zhong; Lanlan Yu; Xiao-Huan Liang; Jenny Yao; Dominique Blanchard; Carlos Bais; Franklin V Peale; Nicholas van Bruggen; Calvin Ho; Jed Ross; Martha Tan; Richard A D Carano; Y Gloria Meng; Napoleone Ferrara
Journal:  Nature       Date:  2007-12-06       Impact factor: 49.962

9.  SDF1alpha/CXCR4 signaling, via ERKs and the transcription factor Egr1, induces expression of a 67-kDa form of glutamic acid decarboxylase in embryonic hippocampal neurons.

Authors:  Yongquan Luo; Justin Lathia; Mohammed Mughal; Mark P Mattson
Journal:  J Biol Chem       Date:  2008-07-07       Impact factor: 5.157

10.  A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization.

Authors:  Marco Seandel; Jason Butler; David Lyden; Shahin Rafii
Journal:  Cancer Cell       Date:  2008-03       Impact factor: 31.743

View more
  46 in total

1.  HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.

Authors:  Nilay Shah; Kideok Jin; Leigh-Ann Cruz; Sunju Park; Helen Sadik; Soonweng Cho; Chirayu Pankaj Goswami; Harikrishna Nakshatri; Rajnish Gupta; Howard Y Chang; Zhe Zhang; Ashley Cimino-Mathews; Leslie Cope; Christopher Umbricht; Saraswati Sukumar
Journal:  Cancer Res       Date:  2013-07-05       Impact factor: 12.701

2.  An essential role for platelet-activating factor in activating mast cell migration following ultraviolet irradiation.

Authors:  Rommel Chacón-Salinas; Limo Chen; Alma D Chávez-Blanco; Alberto Y Limón-Flores; Ying Ma; Stephen E Ullrich
Journal:  J Leukoc Biol       Date:  2013-09-05       Impact factor: 4.962

Review 3.  Pleiotropic effects of prostaglandin E2 in hematopoiesis; prostaglandin E2 and other eicosanoids regulate hematopoietic stem and progenitor cell function.

Authors:  Louis M Pelus; Jonathan Hoggatt
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-06-21       Impact factor: 3.072

4.  Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.

Authors:  Amanda Kirane; Jason E Toombs; Katherine Ostapoff; Juliet G Carbon; Sara Zaknoen; Jordan Braunfeld; Roderich E Schwarz; Francis J Burrows; Rolf A Brekken
Journal:  Clin Cancer Res       Date:  2012-07-24       Impact factor: 12.531

5.  Selective activation of the prostaglandin E2 circuit in chronic injury-induced pathologic angiogenesis.

Authors:  Elvira L Liclican; Van Nguyen; Aaron B Sullivan; Karsten Gronert
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-07-07       Impact factor: 4.799

6.  Prostanoid induces premetastatic niche in regional lymph nodes.

Authors:  Fumihiro Ogawa; Hideki Amano; Koji Eshima; Yoshiya Ito; Yoshio Matsui; Kanako Hosono; Hidero Kitasato; Akira Iyoda; Kazuya Iwabuchi; Yuji Kumagai; Yukitoshi Satoh; Shuh Narumiya; Masataka Majima
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

7.  A study of prostaglandin pathway genes and interactions with current nonsteroidal anti-inflammatory drug use in colorectal adenoma.

Authors:  Todd L Edwards; Martha J Shrubsole; Qiuyin Cai; Guoliang Li; Qi Dai; Douglas K Rex; Thomas M Ulbright; Zhenming Fu; Harvey J Murff; Walter Smalley; Reid Ness; Wei Zheng
Journal:  Cancer Prev Res (Phila)       Date:  2012-05-02

8.  Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor.

Authors:  Chantale Charo; Vijaykumar Holla; Thiruvengadam Arumugam; Rosa Hwang; Peiying Yang; Raymond N Dubois; David G Menter; Craig D Logsdon; Vijaya Ramachandran
Journal:  Pancreas       Date:  2013-04       Impact factor: 3.327

9.  Epigenetic silencing of HOPX promotes cancer progression in colorectal cancer.

Authors:  Hiroshi Katoh; Keishi Yamashita; Mina Waraya; Ofer Margalit; Akira Ooki; Hideaki Tamaki; Hiroyuki Sakagami; Kenichi Kokubo; David Sidransky; Masahiko Watanabe
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

Review 10.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.